Probuphine Panel Review Could Be A Test Of Titan’s Delivery Technology
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA will convene an advisory committee review of the buprenorphine implant for opioid dependence – an established use for the drug, but the first in an extended-release delivery system.
You may also be interested in...
Myovant’s Relugolix Won’t Be Stopped By Missed Endpoint
The miss on improving castration resistance-free survival in Phase III trial is not likely to affect the ongoing FDA review, the company and analysts agree.
BI Finds Right Fit For Digital Therapeutic Partnership With Click
Deal Snapshot: The firms are partnering on a digital therapeutic for schizophrenia in a deal potentially worth $500m.
Consumer Health Brands Will Be Included In Bausch's Spin-Out Of Bausch Part Of Company
“The spin-off will establish two separate companies, a fully integrated, pure play, eye health company built on the iconic Bausch Health brand and a long history of innovation, and an international diversified pharmaceutical company with leading physicians in gastroenterology, dermatology, aesthetics, neurology and an international pharma business,” says CEO Joseph Papa.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: